Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Basal ¹⁸F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography as a prognostic biomarker in patients with locally advanced breast cancer.
García Vicente AM, Soriano Castrejón Á, López-Fidalgo JF, Amo-Salas M, Muñoz Sanchez Mdel M, Álvarez Cabellos R, Espinosa Aunión R. García Vicente AM, et al. Among authors: alvarez cabellos r. Eur J Nucl Med Mol Imaging. 2015 Nov;42(12):1804-13. doi: 10.1007/s00259-015-3102-x. Epub 2015 Jul 9. Eur J Nucl Med Mol Imaging. 2015. PMID: 26156534 Clinical Trial.
Basal (18)F-FDG PET/CT as a predictive biomarker of tumor response for neoadjuvant therapy in breast cancer.
García Vicente AM, Soriano Castrejón A, Pruneda-González RE, Fernández Calvo G, Muñoz Sánchez MM, Álvarez Cabellos R, Espinosa Aunión R, Relea Calatayud F. García Vicente AM, et al. Among authors: alvarez cabellos r. Rev Esp Med Nucl Imagen Mol. 2016 Mar-Apr;35(2):81-7. doi: 10.1016/j.remn.2015.09.001. Epub 2015 Oct 27. Rev Esp Med Nucl Imagen Mol. 2016. PMID: 26521995
Glycolytic activity in breast cancer using 18F-FDG PET/CT as prognostic predictor: A molecular phenotype approach.
Garcia Vicente AM, Soriano Castrejón A, Amo-Salas M, Lopez Fidalgo JF, Muñoz Sanchez MM, Alvarez Cabellos R, Espinosa Aunion R, Muñoz Madero V. Garcia Vicente AM, et al. Among authors: alvarez cabellos r. Rev Esp Med Nucl Imagen Mol. 2016 May-Jun;35(3):152-8. doi: 10.1016/j.remn.2015.08.001. Epub 2015 Oct 27. Rev Esp Med Nucl Imagen Mol. 2016. PMID: 26522003 English, Spanish.
SEOM-TTCC clinical guideline in nasopharynx cancer (2021).
Rueda Domínguez A, Cirauqui B, García Castaño A, Alvarez Cabellos R, Carral Maseda A, Castelo Fernández B, Iglesias Rey L, Rubió-Casadevall J, Arrazubi V, Mesía R. Rueda Domínguez A, et al. Among authors: alvarez cabellos r. Clin Transl Oncol. 2022 Apr;24(4):670-680. doi: 10.1007/s12094-022-02814-x. Epub 2022 Mar 18. Clin Transl Oncol. 2022. PMID: 35303267 Free PMC article.
Identification of ALK-positive patients with advanced NSCLC and real-world clinical experience with crizotinib in Spain (IDEALK study).
Aguado de la Rosa C, Cruz Castellanos P, Lázaro-Quintela M, Dómine M, Vázquez Estévez S, López-Vivanco G, Fírvida Pérez JL, Alonso Romero JL, Ferrera Delgado L, García Girón C, Diz Taín P, Álvarez Álvarez R, Mut Sanchís P, Fernández Cantón I, Manrique Abós I, Martínez Aguillo M, Gómez-Aldaraví Gutiérrez L, Ortega Granados AL, Álvarez Cabellos R, García Sebastián A, García Sifuentes LF, Reguart N. Aguado de la Rosa C, et al. Among authors: alvarez cabellos r. Lung Cancer. 2022 Nov;173:83-93. doi: 10.1016/j.lungcan.2022.09.010. Epub 2022 Sep 19. Lung Cancer. 2022. PMID: 36162227 Free article.
Consolidation treatment with Yttrium-90 ibritumomab tiuxetan after new induction regimen in patients with intermediate- and high-risk follicular lymphoma according to the follicular lymphoma international prognostic index: a multicenter, prospective phase II trial of the Spanish Lymphoma Oncology Group.
Provencio M, Cruz Mora MÁ, Gómez-Codina J, Quero Blanco C, Llanos M, García-Arroyo FR, de la Cruz L, Gumá Padró J, Delgado Pérez JR, Sánchez A, Alvarez Cabellos R, Rueda A; Gotel (Spanish Lymphoma Oncology Group). Provencio M, et al. Among authors: alvarez cabellos r. Leuk Lymphoma. 2014 Jan;55(1):51-5. doi: 10.3109/10428194.2013.790544. Epub 2013 Jun 12. Leuk Lymphoma. 2014. PMID: 23573825 Clinical Trial.
The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy.
Gómez Rueda A, Taus Á, Álvarez Álvarez R, Bernabé-Caro R, Chara L, López-Brea M, Vilà L, Sala González MÁ, Del Barrio Díaz Aldagalán A, Esteban Herrera B, López Castro R, Álvarez Cabellos R, Doménech M, Falagan S, Moreno Vega A, Aguado C, Barba A, Delgado Ureña MT, Isla D, Bellido Hernández L, Fírvida Pérez JL, Juan-Vidal Ó, Massutí B, Mielgo-Rubio X, Ortega AL, Catot S, Dómine M, Escoín-Pérez C, García Navalón F, Gil-Bazo I, Muñoz S, Rodríguez-Abreu D, Villatoro Roldán RM, Alonso-Jáudenes Curbera G, León-Mateos L, Padilla A, Paredes Lario A, Sánchez-Torres JM, Garrido P; Spanish Lung Cancer Group. Gómez Rueda A, et al. Among authors: alvarez cabellos r. Clin Transl Oncol. 2024 Mar 21. doi: 10.1007/s12094-024-03404-9. Online ahead of print. Clin Transl Oncol. 2024. PMID: 38512450